FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:53 July 2, 1998 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In 1996, several European gastroenterologists recommended that first-line treatment of Helicobacter pylori infection should consist of a proton-pump inhibitor combined with two of the following: clarithromycin, a nitroimidazole (metronidazole or tinidazole), and amoxicillin.¹ In the case of treatment failure, either a second course of this triple regimen or quadruple therapy (omeprazole plus bismuth-based triple therapy) is advisable. However, because patient compliance with and tolerance of quadruple therapy is low, alternative treatments are needed for patients who have had no response to two or more courses of a standard triple regimen.

Preliminary in vitro studies have shown that . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Gisbert, J. P. (2009). Review: Second-line rescue therapy of Helicobacter pylori infection. Therapeutic Advances in Gastroenterology 2: 331-356 [Abstract]  
• Kusters, J. G., van Vliet, A. H. M., Kuipers, E. J. (2006). Pathogenesis of Helicobacter pylori Infection. Clin. Microbiol. Rev. 19: 449-490 [Abstract] [Full Text]  
• Heep, M., Odenbreit, S., Beck, D., Decker, J., Prohaska, E., Rieger, U., Lehn, N. (2000). Mutations at Four Distinct Regions of the rpoB Gene Can Reduce the Susceptibility of Helicobacter pylori to Rifamycins. Antimicrob. Agents Chemother. 44: 1713-1715 [Abstract] [Full Text]  
• Heep, M., Rieger, U., Beck, D., Lehn, N. (2000). Mutations in the Beginning of the rpoB Gene Can Induce Resistance to Rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44: 1075-1077 [Abstract] [Full Text]  
• Heep, M., Beck, D., Bayerdörffer, E., Lehn, N. (1999). Rifampin and Rifabutin Resistance Mechanism in Helicobacter pylori. Antimicrob. Agents Chemother. 43: 1497-1499 [Abstract] [Full Text]